Hospitalized Patients with Oral Cavity Cancer and Ulcerative Mucositis: Implications for Key Cost Drivers and Disparities
Reports · 26.06.2026 · 9 (3) · 203
DOI: 10.3390/reports9030203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reports, online erschienen am 26.06.2026. Verfasst von Lauryn Rudin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University at Buffalo, Buffalo, NY 14203, USA. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaleida Troup Funding.
Abstract (Originalsprache)
Background
Cancer treatment-induced ulcerative mucositis (UM) is a debilitating toxicity in patients with cancers of the lip, oral cavity, and pharynx (CLOP). This study evaluated the association of chemotherapy-induced (CT-UM) and radiotherapy-induced ulcerative mucositis (RT-UM) with burden of illness (BOI), focusing on hospital length of stay (LOS) and total charges, and examined disparities in outcomes.
Methods
This retrospective cohort study analyzed 2019 National Inpatient Sample (NIS) data. Adult patients (≥18 years) hospitalized with CLOP (ICD-10-CM C00–C14) undergoing inpatient surgery, chemotherapy, or radiotherapy were included. CT-UM (K12.31) and RT-UM (K12.33) were identified as secondary diagnoses. Survey-weighted generalized linear models (negative binomial for LOS; gamma for charges) adjusted for demographics, comorbidities (Elixhauser score), insurance, income, and Diagnosis-Related Groups (DRG; surgical vs. medical) were used.
Results
Among 59,710 weighted CLOP hospitalizations, 820 had CT-UM and 1010 had RT-UM. Patients with UM were younger and had varying comorbidity burdens. Unadjusted analyses showed prolonged geometric mean LOS for CT-UM (5.66 vs. 3.81 days, p < 0.001) and RT-UM (4.95 vs. 3.81 days, p = 0.001), with lower total charges ($48,645 and $42,938 vs. $56,267). Multivariable analyses confirmed RT-UM was associated with increased LOS (adjusted coefficient 1.33, 95% CI 1.14–1.55) but lower charges (0.67, 95% CI 0.56–0.81). In patients >50 years, CT-UM showed stronger effects (LOS 1.80, 95% CI 1.49–2.15; charges 0.79, 95% CI 0.65–0.98). Significant disparities were observed: females, Black and Hispanic patients, and Medicaid beneficiaries experienced greater BOI (prolonged LOS and/or higher charges in subgroups). Associations persisted in DRG- and procedure-stratified sensitivity analyses, suggesting treatment interruptions as a key driver.
Conclusions
Ulcerative mucositis in hospitalized CLOP patients is associated with prolonged LOS but lower charges, likely due to treatment modifications, and disproportionately affects vulnerable populations. These findings highlight the need for proactive oral care protocols, multidisciplinary integration, and equity-focused interventions to reduce the burden of this toxicity and improve cancer treatment outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University at Buffalo, Buffalo, NY 14203, USA.
- Division of Hematology and Oncology, Department of Medicine, University at Buffalo, Buffalo, NY 14203, USA.
- City of Hope Comprehensive Cancer Center, Duarte CA and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical System, Los Angeles, CA 90048, USA.
- Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY 14203, USA.
- College of Dental Medicine, Nova Southeastern University, Davie, FL 33328, USA.
- UConn Health: Neag Comprehensive Cancer Center, University of Connecticut, 135 Dowling Way 4th Floor, Farmington, CT 06030, USA.
ORCID-Profile: Lauryn Rudin, Poolakkad S Satheeshkumar
Förderung
- Kaleida Troup Funding
Zitieren
APA
Rudin, L., Pili, R., Epstein, J. B., Aljanahi, K., Cordova, D., Rajesh, R., Meleveedu, K., & Satheeshkumar, P. S. (2026). Hospitalized Patients with Oral Cavity Cancer and Ulcerative Mucositis: Implications for Key Cost Drivers and Disparities. Reports, 9(3), 203. https://doi.org/10.3390/reports9030203
Vancouver
Rudin L, Pili R, Epstein JB, Aljanahi K, Cordova D, Rajesh R, et al. Hospitalized Patients with Oral Cavity Cancer and Ulcerative Mucositis: Implications for Key Cost Drivers and Disparities. Reports. 2026;9(3):203. doi:10.3390/reports9030203
BibTeX
@article{Rudin2026,
author = {Rudin, Lauryn and Pili, Roberto and Epstein, Joel B and Aljanahi, Karrar and Cordova, Diggory and Rajesh, Richa and Meleveedu, Kapil and Satheeshkumar, Poolakkad S},
title = {Hospitalized Patients with Oral Cavity Cancer and Ulcerative Mucositis: Implications for Key Cost Drivers and Disparities},
journal = {Reports},
year = {2026},
volume = {9},
number = {3},
pages = {203},
doi = {10.3390/reports9030203}
}
EUVIMED